Chemical inhibitors of PLEKHA9 can influence its function through various pathways by directly targeting processes that the protein is known to be involved with. GW4869 disrupts sphingolipid metabolism, which is crucial for membrane composition and signaling. By altering the sphingolipid composition in the membrane, GW4869 can inhibit PLEKHA9's associated signaling. Another inhibitor, MAFP, targets phospholipase A2, reducing arachidonic acid and lysophospholipids production. Since PLEKHA9 requires lipid signaling molecules for its function, the reduction in these molecules by MAFP results in the inhibition of PLEKHA9. Similarly, U73122 impedes phospholipase C, thereby inhibiting PLEKHA9 by halting the production of diacylglycerol and inositol trisphosphate, which are pivotal for PLEKHA9's role in signal transduction.
Furthermore, PD98059 and LY294002, by inhibiting MEK and PI3K respectively, can impede the MAPK/ERK and PI3K/AKT pathways. Since PLEKHA9 is implicated in these pathways through its signaling roles, the inhibitors can suppress PLEKHA9's function. Wortmannin, much like LY294002, disrupts PI3K/AKT signaling and is capable of inhibiting PLEKHA9 by impacting its interaction with phosphoinositides. SB203580 and SP600125, which target p38 MAPK and JNK respectively, can inhibit PLEKHA9 by affecting stress-related signal transduction and cellular responses to cytokines, both processes that involve PLEKHA9. BAPTA, by sequestering calcium, prevents calcium-dependent signaling, consequently inhibiting PLEKHA9's potential involvement in such processes. Y-27632 and ML7, which inhibit ROCK and myosin light chain kinase respectively, can disrupt actin cytoskeleton dynamics and cellular contractility, thereby inhibiting PLEKHA9's role in related signaling pathways. Lastly, Genistein targets tyrosine kinases, which are responsible for phosphorylation events within pathways that PLEKHA9 is known to participate in, leading to its inhibition. Each of these chemicals interfere with specific signaling events or pathways that are essential for the functional acti
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 inhibits sphingomyelinase, which can disrupt sphingolipid metabolism and potentially inhibit PLEKHA9 by altering membrane composition and associated signaling. | ||||||
MAFP | 188404-10-6 | sc-203440 | 5 mg | $219.00 | 4 | |
MAFP inhibits phospholipase A2, reducing the production of arachidonic acid and lysophospholipids, which can inhibit PLEKHA9 by limiting lipid signaling molecules that regulate its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which can inhibit PLEKHA9 by preventing the activation of the MAPK/ERK pathway, potentially affecting PLEKHA9's role in signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which can inhibit PLEKHA9 by blocking the PI3K/AKT pathway, a pathway that PLEKHA9 may be involved in through its phosphoinositide binding domain. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, which can inhibit PLEKHA9 by disrupting the PI3K/AKT signaling pathway, potentially affecting PLEKHA9's interactions with phosphoinositides. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, which can inhibit PLEKHA9 by affecting downstream signaling that PLEKHA9 may be involved in, particularly in stress-related signal transduction. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can inhibit PLEKHA9 by altering the JNK signaling pathway, potentially impacting PLEKHA9's role in cellular responses to cytokines and stress. | ||||||
BAPTA, Free Acid | 85233-19-8 | sc-201508 sc-201508A | 100 mg 500 mg | $68.00 $267.00 | 10 | |
BAPTA chelates calcium, which can inhibit PLEKHA9 by preventing calcium-dependent signaling processes that PLEKHA9 is involved in through its calcium-binding domain. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits ROCK, which can inhibit PLEKHA9 by modifying the actin cytoskeleton dynamics and associated signaling pathways that PLEKHA9 is part of. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML7 inhibits myosin light chain kinase, which can inhibit PLEKHA9 by disrupting cellular contractility and motility signaling pathways that PLEKHA9 may interact with. | ||||||